GMS 6540 MODULE 3 TARGETED THERAPY EXAM QUESTIONS
AND VERIFIED ANSWERS GRADED A++
Cetuximab
tyrosine kinase inhibitor, inhibit ATP binding --> prevents kinase activity, is
an antibody, administered as a loading dose + weekly maintenance doses,
for colon cancer and head/neck squamous cell carcinoma
Erlotinib
tyrosine kinase inhibitor, inhibit ATP binding --> prevents kinase activity,
competitive inhibitor, oral, primarily for NSCLC with mutant EGFR, rash and
diarrhea, met by CYP3A4, PPIs inhibit its absorption by 50%
Gefitinib
AND VERIFIED ANSWERS GRADED A++
Cetuximab
tyrosine kinase inhibitor, inhibit ATP binding --> prevents kinase activity, is
an antibody, administered as a loading dose + weekly maintenance doses,
for colon cancer and head/neck squamous cell carcinoma
Erlotinib
tyrosine kinase inhibitor, inhibit ATP binding --> prevents kinase activity,
competitive inhibitor, oral, primarily for NSCLC with mutant EGFR, rash and
diarrhea, met by CYP3A4, PPIs inhibit its absorption by 50%
Gefitinib
